1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Crossject SA

Crossject SA

1.30
EUR
-0.01
(-0.61%)
99.88MMarket Cap
Mar 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
0.02
- -
0.03
0.03
- -
- -
- -
- -
Basic EPS, GAAP
-0.34
-0.6
-0.79
-0.84
-0.8
-0.76
-0.34
-0.4
-0.4
-0.3
-0.23
-0.28
-0.2
- -
Free Cash Flow per Basic Share
-0.39
-1.1
-0.92
-1.33
-0.97
-0.8
-0.48
-0.47
-0.48
-0.32
-0.34
-0.25
-0.21
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.21
2.01
1.22
0.8
0.65
0.12
0.14
-0.05
-0.2
0.07
-0.14
-0.06
-0.09
-0.06
Tangible Book Value per Share
-0.19
1.69
0.9
0.48
0.22
-0.22
-0.16
-0.35
-0.54
-0.21
-0.43
-0.27
-0.25
-0.27
Basic Weighted Avg Shares
5
7
7
8
10
14
21
25
27
37
37
46
52
44
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
1
- -
1
1
- -
- -
- -
- -
Operating Margin (%)
- -
-12,769,145
- -
- -
- -
- -
-1,695.59
- -
-1,296.38
-1,392.87
-7,996.55
- -
- -
- -
Depreciation Expense
1
1
1
3
2
4
4
5
5
6
3
5
6
- -
Net Income, GAAP
-2
-4
-6
-7
-8
-11
-7
-10
-11
-11
-9
-13
-10
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-10,840,172.5
- -
- -
- -
- -
-1,434.74
- -
-1,184.87
-1,169.5
-5,958.62
- -
- -
- -
Working Capital
3
11
6
3
3
6
9
15
11
8
4
9
6
9
LT Debt
1
- -
- -
3
4
9
13
24
26
14
19
21
19
21
Total Equity
1
14
9
6
6
2
3
-1
-5
3
-5
-3
-5
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-56.2
-48.85
-88.36
-123.06
-276.78
-307.33
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
- -
3
3
LT Borrowings
19
21
21
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
42
46
Market Capitalization
179
68
100

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
11
16
16
Cash, Cash Equivalents & STI
2
6
7
Accounts Receivable, Net
5
1
4
Inventories
3
4
3
Total Current Liabilities
7
9
7
Payables & Accruals
- -
- -
- -
ST Debt
- -
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-18.7%
-5.44%
82.34%
Free Cash Flow
6.88%
-0.95%
-5.54%
Net Income, GAAP
9.59%
3.92%
-18.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.23
2024
- -
- -
-0.28
2025
- -
- -
-0.2

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Patrick Alexandre
Full Time Employees
103
Sector
Health technology
Industry
Medical specialties
Address
6 Rue Pauline Kergomard Dijon BF France 21000
IPO Date
Feb 20, 2014
Website
crossject.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Crossject S.A. (Euronext: ALCJ.PA) develops and manufactures needle-free, pre-filled, single-use auto-injectors based on its proprietary ZENEO platform for the rapid delivery of emergency medications via intradermal, subcutaneous, and intramuscular routes; core products in its pipeline include ZEPIZURE (midazolam for status epilepticus, poisoning, and epileptic seizures targeting FDA EUA submission in Q2 2025 and NDA in mid-2026), CJT-L15 (hydrocortisone for acute adrenal insufficiency), CJT-L21 (epinephrine for anaphylactic shock), CJT-L20 (terbutaline for severe asthma), CJT-L11 (sumatriptan for migraine and cluster headache), CJT-L9 (methotrexate for rheumatoid arthritis), and CJT-L16 (naloxone for opioid overdose), all pursuing FDA 505(b)(2) NDA pathways between 2026 and 2028. Founded in 2001 and headquartered in Dijon, France, with manufacturing sites in Dijon and Gray, the company operates primarily in Europe and pursues U.S. commercialization through partnerships, targeting patients and healthcare providers in emergency situations such as epilepsy, allergies, adrenal crises, and overdoses. Recent developments include a €5 million financing completion with Vatel Capital in November 2025, an €11.3 million BARDA funding extension in September 2025 for ZEPIZURE development, a June 2025 €5 million capital increase, a $60 million BARDA contract for ZEPIZURE, U.S. infrastructure expansion with key hires like a Chief Operating Officer and Chief Medical Officer in 2024, geographic commercialization extensions for ZEPIZURE in Europe, a renewed U.S. Department of Defense CRADA in December 2024, and successful ISO/GMP audits confirming manufacturing readiness.